

Supplementary Table 8. Demographic and clinical characteristics at index date according to DBP level after 6 months of treatment

Variable	DBP level after 6 months of treatment, mmHg ^a						Total	p value
	< 60 (n = 101)	60–69 (n = 1,005)	70–79 (n = 4,937)	80–89 (n = 4,178)	90–99 (n = 734)	≥ 100 (n = 88)		
Age at index date, yr	71.59 ± 9.95 (36 (35.64))	67.30 ± 9.52 (424 (42.19))	60.83 ± 10.13 (2,299 (46.57))	55.35 ± 10.76 (2,321 (55.55))	50.66 ± 10.92 (444 (60.49))	47.78 ± 10.42 (58 (65.91))	58.66 ± 11.49 (5,582 (50.55))	< 0.001
Male sex	152.30 ± 17.78	148.15 ± 18.12	147.74 ± 17.65	150.00 ± 18.38	156.81 ± 21.75	162.41 ± 23.95	149.39 ± 18.50	0.010
SBP, mmHg	72.99 ± 12.76	80.50 ± 11.27	85.88 ± 11.06	91.84 ± 11.76	98.53 ± 13.71	104.72 ± 15.63	88.52 ± 12.59	< 0.001
DBP, mmHg	71.18 ± 14.96	76.21 ± 14.53	76.67 ± 14.13	77.34 ± 14.52	80.39 ± 14.15	87.47 ± 16.78	77.14 ± 14.42	< 0.001
Pulse rate, bpm								< 0.001
Cardiovascular risk								< 0.001
High-risk	34 (33.7)	321 (31.94)	2,335 (47.30)	2,260 (54.09)	393 (53.54)	38 (43.18)	5,381 (48.73)	
History of CVD	31 (30.7)	308 (30.65)	885 (17.93)	557 (13.33)	96 (13.08)	17 (19.32)	1,894 (17.15)	< 0.001
CKD	27 (26.7)	255 (25.37)	769 (15.58)	425 (10.17)	65 (8.86)	9 (10.23)	1,550 (14.04)	0.063
DM	18 (17.8)	215 (21.39)	602 (12.19)	389 (9.31)	59 (8.04)	12 (13.64)	1,295 (11.73)	< 0.001
Moderate risk	12 (11.9)	116 (11.54)	780 (15.80)	751 (17.98)	147 (20.03)	18 (20.45)	1,823 (16.51)	
LVH	12 (11.9)	139 (13.7)	668 (13.4)	604 (14.4)	107 (14.5)	21 (24.0)	1,551 (14.05)	0.050
Vascular stiffness	6 (5.9)	64 (6.37)	236 (4.78)	222 (5.31)	47 (6.40)	7 (7.95)	582 (5.27)	0.153
Metabolic syndrome ^a	31 (30.7)	287 (28.56)	950 (19.24)	624 (14.94)	81 (11.04)	14 (15.91)	1,987 (17.99)	< 0.001
Low-risk	56 (55.45)	568 (56.52)	1,822 (36.91)	1,167 (27.93)	194 (26.43)	32 (36.36)	3,839 (34.76)	

Values are presented as mean ± standard deviation or number (%). If cells with an expected frequency of 5 or less exceed 20%, Fisher's exact test will be performed instead of chi-square test. If normality test is not significant, Kruskal-Wallis test will be performed instead of one-way analysis of variance (ANOVA). DBP, diastolic blood pressure; SBP, systolic blood pressure; HTN, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; DM, diabetes mellitus; LVH, left ventricular hypertrophy.

^aIf patients with metabolic syndrome have additional risk factors of high-risk group, they were allocated in high-risk group. That is why the number of metabolic syndromes is more than that of moderate risk group.